Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts

Moderna trimmed its 2025 revenue forecast to $1.5 billion-$2.2 billion after UK COVID vaccine deliveries were deferred to next year, causing its shares to decline 7%. This overshadowed a better-than-expected second-quarter loss of $2.13 per share and revenue of $142 million, despite a 41% year-over-year drop. Facing slumping demand for COVID-19 shots and pipeline delays, the company is implementing significant cost reductions and relying on new mRNA products, such as its COVID-flu combo shot, to reestablish growth, though the UK deferral does not impact the total value of its multiyear contract.

Analysis

Moderna's revised 2025 revenue forecast, lowered to a range of $1.5 billion to $2.2 billion, triggered a 7% share price decline, overshadowing an otherwise positive second-quarter report. The guidance cut stems from the deferral of UK COVID vaccine deliveries into 2026, a timing shift that pressures near-term revenue recognition despite not altering the total contract value. For the quarter, the company demonstrated strong operational control, posting revenue of $142 million, which, while down 41% year-over-year, surpassed analyst estimates of $112.9 million. More significantly, its adjusted loss of $2.13 per share was substantially narrower than the expected $2.97 loss, a result attributed to better-than-anticipated spring booster uptake and aggressive cost reductions totaling $800 million in the first half of 2025. This performance occurs within the challenging context of a post-pandemic market, where quarterly Spikevax sales of $114 million are a stark contrast to its $18.4 billion peak in 2022. Management remains cautiously optimistic about autumn vaccine demand but acknowledges that a clear picture will only emerge at the end of the third quarter, placing significant weight on future performance and the success of its new mRNA product pipeline to drive a return to growth.

Key Decisions for Investors

• Investors should weigh the negative impact of the lowered 2025 revenue guidance against the company's demonstrated ability to outperform earnings expectations through aggressive cost management and unexpected strength in seasonal demand.
• The deferral of UK revenue highlights a key risk in timing and government purchasing cycles, making the stock sensitive to future contract announcements and fiscal policies of major purchasers.
• The investment thesis is now heavily dependent on two forward-looking catalysts: the strength of the upcoming autumn vaccine season and tangible progress in the non-COVID mRNA pipeline, making Q3 results and pipeline updates critical inflection points to monitor.